An update from the phase 2 LEGEND trial shows that the investigational nonviral gene therapy detalimogene voraplasmid has achieved a 62% complete response rate at six months in patients with high-risk ...
Intuitive Surgical, Inc. stock: da Vinci robotics leader with 80% share, recurring revenue, fast procedure growth and solid ...
The annual rate of radical hysterectomies performed by gynecologic oncologists in the US declines significantly despite a doubling of the workforce.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback